Henry Grabowski is an authority on the economics of the pharmaceutical industry, the economics of innovation, and government regulation of business. His research examines government policy actions and their effects on the pharmaceutical industry, pharmaceutical research and development costs and returns, and questions involving generic and biosimilar competition.
Professor Grabowski has extensive testifying experience in deposition and trial. His primary focus is on evaluating commercial success and irreparable harm issues for small molecule and biologic drugs in Hatch-Waxman (Paragraph IV) patent litigation and inter partes review proceedings. He has also provided expert testimony in matters related to antitrust and competition, breach of contract, false claims, and other disputes related to intellectual property.
Professor Grabowski has published over seventy-five articles in leading academic journals, and written chapters for nearly thirty books. He has testified in front of congressional committees on policy issues related to his research. Professor Grabowski has also served as an advisor for the Institute of Medicine, the U.S. Federal Trade Commission, the National Academy of Sciences, the Office of Technology Assessment, and the General Accounting Office.
2020 IAM Guide to Leading Patent Professionals
Reverse Payments Settlement Analysis
Glaxo–Burroughs Wellcome Merger
In re Ovcon Antitrust Litigation